Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34385537

about

Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials Salmonella as a vaccine delivery vehicle Gene therapy in pancreatic cancer.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.Trial watch: Naked and vectored DNA-based anticancer vaccines Current status and future directions of anti-angiogenic therapy for gliomas Trial watch: DNA vaccines for cancer therapy.Live-attenuated bacteria as a cancer vaccine vector.Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer.Intracellular delivery of biologic therapeutics by bacterial secretion systems.Trial Watch: DNA vaccines for cancer therapy.A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated

P2860

Q26781538-3CDAA8F7-D527-4408-8347-881BA16374D5 Q27011946-6E9F2936-82F4-4715-9996-809B8A1C693C Q34302954-ED139611-3F0C-406C-A838-452BEE1C41D8 Q35798947-034DCAE7-95BE-45F5-9DC6-933011AD7A16 Q35798986-B0444393-7531-47AD-B8F2-20A8EC952394 Q36618235-6C99FC63-C085-4425-9627-2A36049AE0C6 Q36845824-89C06849-0B77-433F-BAAD-F08853A16D46 Q38152473-73BF705A-DD3F-4E40-A28A-DF750D7A976B Q38165930-48BE6021-AD9A-494F-A313-35D6609E8114 Q38734240-C55C4EA2-7AF3-413F-BDDD-8DA959CBF34E Q42552005-5D423900-9606-4BDB-9F0B-350BB371110A Q52597561-7D318BB8-4F80-47FD-86EB-5871FD9112F9 Q57300412-FD9ED573-8362-445A-8954-92C57C6D2646

P2860

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34385537

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@ast

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@en

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@nl

type

label

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@ast

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@en

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@nl

prefLabel

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@ast

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@en

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@nl

P1433

Q34385537-B9BA7BD3-B4F3-4AE0-BCB3-8E568C349C8B

P1476

Q34385537-E2BE5141-F95E-4498-8B3F-0E8127A7D6DA

P2093

Q34385537-093B8904-FBD6-491E-B088-C300C7216EF2

Q34385537-1D8EFA62-36D3-4B05-8658-DCBCC689A78B

Q34385537-27167664-6655-4332-98B2-68ED9BC31A73

Q34385537-4B345E90-E9D1-42D8-BD30-9E6E03EA2D5A

Q34385537-622DCB06-1C81-4CD2-8A33-7BA79D2B4160

Q34385537-A3C06352-E3C1-4EBE-9520-77B81CFF1A1F

Q34385537-B57F87D3-40E1-4C0C-A02F-B035718FADCE

Q34385537-CCFA041D-0E3D-4874-82DC-88429CAA6A1E

Q34385537-CD631A73-ABBC-4FA0-BC35-BA0931B6D260

Q34385537-D00C2A1A-CEFB-426E-A617-82E0C5B53CFF

P2860

Q34385537-048FBA56-4CAB-44F6-AD92-D6A0205C8D08

Q34385537-0745144F-F1F3-4A6D-B0CA-50B983C7157C

Q34385537-0BBA3490-36A1-49BB-9661-049D68556232

Q34385537-12845528-E436-48BB-AEDF-E9D52D2D53E1

Q34385537-1C21D6EF-1570-4235-B679-B72F664EB4EF

Q34385537-249D98A3-C4F5-4C28-887D-54B926B99D3D

Q34385537-26B7178D-A3BA-4445-95FB-749D4F37AEC3

Q34385537-2C205830-8EB6-4627-98EB-05AFA594932A

Q34385537-2D5EA5BB-ED33-4F1C-BE06-ABD8561C5A4A

Q34385537-3BD8F698-EA05-4B3A-A407-2081E2F64647

P2888

Q34385537-A28971F8-ED7C-4C43-A594-98F04CED5A59

P304

Q34385537-DBA06BC8-EFAE-452C-AE5F-B3BA27014722

P31

Q34385537-D62EE423-6220-490A-95B2-79712FFE881D

P356

Q34385537-F6FD6EE2-E734-4BB9-A288-DAEA5038072C

P407

Q34385537-1109AB3D-D15A-4D58-BDE8-B211025C7032

P478

Q34385537-27815396-C937-4DED-8573-8CD75E2A75A5

P50

Q34385537-15047A16-6ED1-47B7-AC45-D05AA7BD30FA

Q34385537-C76E9EF0-3DB7-44DF-BE8C-2263DF43115B

Q34385537-EF8D0760-BA0F-4A91-BF20-DF72FAC6A852

P577

Q34385537-C01480A4-9D8B-4F45-AF1D-7C5C0DD08F10

P5875

Q34385537-10CBF679-1BA2-42B2-A3A6-DBE0793DAC97

P6179

Q34385537-F99342B3-A231-448A-810C-4FB5949CFB1D

P698

Q34385537-7C4DC355-F7F5-4E70-8F28-C4CC2A06AC91

P921

Q34385537-DDF64680-825C-4FA1-A816-3FEFDEEF2045

P932

Q34385537-158E02DB-0DF4-43AF-9286-E1AAA09C6360

P356

1471-2407-12-361

P1433

P1476

Double-blind, placebo-controll ...... ly advanced pancreatic cancer.

@en

P2093

Andreas G Niethammer

http://www.w3.org/2001/XMLSchema#string

Christine Leowardi

http://www.w3.org/2001/XMLSchema#string

Friedrich H Schmitz-Winnenthal

http://www.w3.org/2001/XMLSchema#string

Heinz Lubenau

http://www.w3.org/2001/XMLSchema#string

Lars Grenacher

http://www.w3.org/2001/XMLSchema#string

Marco Springer

http://www.w3.org/2001/XMLSchema#string

Markus W Buchler

http://www.w3.org/2001/XMLSchema#string

Moritz Koch

http://www.w3.org/2001/XMLSchema#string

Mustafa Akhisaroglu

http://www.w3.org/2001/XMLSchema#string

Nicolas Hohmann

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

Typhoid and paratyphoid fever

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

A phase 3 trial of bevacizumab in ovarian cancer.

Sunitinib and other targeted therapies for renal cell carcinoma.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Vaccines targeting the neovasculature of tumors

P2888

1471-2407-12-361

P304

361

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-361

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Walter E Haefeli

P577

2012-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230706158

http://www.w3.org/2001/XMLSchema#string

P6179

1044632467

http://www.w3.org/2001/XMLSchema#string

P698

22906006

http://www.w3.org/2001/XMLSchema#string

P921

P932

3493262

http://www.w3.org/2001/XMLSchema#string